drugset / Trial / NCT03556904
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
RandomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic castration-resistant prostate cancer.
Timeline
- Start
- 2018-12-10
- Primary completion
- 2023-07-28
- Completion
- 2023-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Cabazitaxel | Other / unclassified | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |